BioGaia AB (LTS:0GTN) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioGaia AB's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BioGaia AB could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for BioGaia AB's Cash-to-Debt or its related term are showing as below:

LTS:0GTN' s Cash-to-Debt Range Over the Past 10 Years
Min: 24.59 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, BioGaia AB's highest Cash to Debt Ratio was No Debt. The lowest was 24.59. And the median was No Debt.

LTS:0GTN's Cash-to-Debt is ranked better than
99.62% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs LTS:0GTN: No Debt

BioGaia AB Cash-to-Debt Historical Data

The historical data trend for BioGaia AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioGaia AB Cash-to-Debt Chart

BioGaia AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

24.59

141.14

142.76

No Debt

BioGaia AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of BioGaia AB's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Cash-to-Debt falls into.

BioGaia AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioGaia AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

BioGaia AB had no debt ⁽¹⁾.

BioGaia AB's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

BioGaia AB had no debt ⁽¹⁾.

BioGaia AB (LTS:0GTN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioGaia AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGaia AB (LTS:0GTN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (LTS:0GTN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BIOGY:USA BGLAF:USA BIOG B:Sweden BGLA:Germany

Address

Kungsbroplan 3A, Stockholm, SWE, SE-112 27

Website

https://www.biogaia.se

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB (LTS:0GTN) Headlines

No Headlines

BioGaia AB (LTS:0GTN) Cash-to-Debt : No Debt (1) (As of Dec. 2023)